Subscribe
Companies are continuing to grow quickly, but the market isn鈥檛 rewarding them
We study research efficiency to pick out the sector鈥檚 winners
Fears about the erosion of future revenues as patents expire have weighed on Merck鈥檚 valuation
Conservative revenue recognition policies mean it is bringing in more cash than its bottom line suggests
Higher interest rates will also make it difficult for any emerging businesses to compete
After parting ways with its chief executive, the Danish pharmaceutical company needs to revive its appeal
The fiscal can is being kicked down the road
A step change in fiscal policy has boosted a range of contractors
A relaxation in the trade war and the elevation of Scott Bessent is good news for businesses, but plenty of issues remain
The group is outshining rivals, with industry-leading margins and a model fit for tougher times
